Donlon NE, Davern M, Sheppard A, O'Connell F, Moran B, Nugent TS, Heeran A, Phelan JJ, Bhardwaj A, Butler C, Ravi N, Donohoe CL, Lynam-Lennon N, Maher S, Reynolds JV, Lysaght J. Potential of damage associated molecular patterns in synergising radiation and the immune response in oesophageal cancer. World J Gastrointest Oncol 2023; 15(8): 1349-1365 [PMID: 37663943 DOI: 10.4251/wjgo.v15.i8.1349]
Corresponding Author of This Article
Noel E Donlon, MD, PhD, Assistant Professor, Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity Translational Medicine Institute and Trinity St James’s Cancer Institute, Trinity College Dublin, St James’s Hospital, James's Street Dublin 8, Dublin D08, Ireland. donlonn@tcd.ie
Research Domain of This Article
Immunology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Aug 15, 2023; 15(8): 1349-1365 Published online Aug 15, 2023. doi: 10.4251/wjgo.v15.i8.1349
Potential of damage associated molecular patterns in synergising radiation and the immune response in oesophageal cancer
Noel E Donlon, Maria Davern, Andrew Sheppard, Fiona O'Connell, Brendan Moran, Timothy S Nugent, Aisling Heeran, James J Phelan, Anshul Bhardwaj, Christine Butler, Narayanasamy Ravi, Claire L Donohoe, Niamh Lynam-Lennon, Stephen Maher, John V Reynolds, Joanne Lysaght
Noel E Donlon, Maria Davern, Andrew Sheppard, Fiona O'Connell, Brendan Moran, Timothy S Nugent, Aisling Heeran, James J Phelan, Anshul Bhardwaj, Christine Butler, Narayanasamy Ravi, Claire L Donohoe, Niamh Lynam-Lennon, Stephen Maher, John V Reynolds, Joanne Lysaght, Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity Translational Medicine Institute and Trinity St James’s Cancer Institute, Trinity College Dublin, St James’s Hospital, Dublin D08, Ireland
Author contributions: Donlon NE and Davern M contributed equally to writing and experimentation; all other authors contributed to sample acquisition and data collection; Reynolds JV and Lysaght J contributed to supervision.
Institutional review board statement: This body of work was ethically approved by the SJH/TUH Ethics Committee.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Noel E Donlon, MD, PhD, Assistant Professor, Cancer Immunology and Immunotherapy Group, Department of Surgery, Trinity Translational Medicine Institute and Trinity St James’s Cancer Institute, Trinity College Dublin, St James’s Hospital, James's Street Dublin 8, Dublin D08, Ireland. donlonn@tcd.ie
Received: January 14, 2023 Peer-review started: January 14, 2023 First decision: March 14, 2023 Revised: March 29, 2023 Accepted: June 25, 2023 Article in press: June 25, 2023 Published online: August 15, 2023
ARTICLE HIGHLIGHTS
Research background
The incidence of oesophageal adenocarcinoma (OAC) is increasing exponentially annually as a consequence of obesity. The current therapeutics remain chemo(radio)therapy with mixed responses. The purpose of this work is to determine baseline damage associated molecular pattern (DAMP) expression in OAC patients as well as the effects of chemo(radio)therapy on DAMP expression.
Research motivation
To identify new therapeutic strategies in OAC.
Research objectives
This study aims to interrogate OAC DAMP expression.
Research methods
Patient tumour and serum samples were assessed for DAMP expression as well as tumour cell lines to mimic the tumour microenvironment.
Research results
Conventional therapies increase DAMP expression.
Research conclusions
OAC is an immunogenic cancer and must be exploited to harness immune mediated anti tumour responses.
Research perspectives
This is the first study of its kind in esophageal cancer looking at the baseline expression of DAMPs which is viewed as a surrogate marker of immunogenicity. Furthermore, it looks at the effects of conventional therapies on the immunogenicity of OAC.
